| Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment JH Kim, DH Sinn, W Kang, GY Gwak, YH Paik, MS Choi, JH Lee, KC Koh, ... Hepatology 66 (2), 335-343, 2017 | 207 | 2017 |
| Innate-like cytotoxic function of bystander-activated CD8+ T cells is associated with liver injury in acute hepatitis A J Kim, DY Chang, HW Lee, H Lee, JH Kim, PS Sung, KH Kim, SH Hong, ... Immunity 48 (1), 161-173. e5, 2018 | 166 | 2018 |
| Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients KS Jung, JY Park, YE Chon, HS Kim, W Kang, BK Kim, SU Kim, DY Kim, ... Journal of gastroenterology 51, 830-839, 2016 | 121 | 2016 |
| Hepatitis C virus infection enhances TNFá‐induced cell death via suppression of NF‐êB J Park, W Kang, SW Ryu, WI Kim, DY Chang, DH Lee, DY Park, YH Choi, ... Hepatology 56 (3), 831-840, 2012 | 96 | 2012 |
| Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis SU Kim, SH Ahn, JY Park, W Kang, YN Park, CY Chon, KH Han Journal of clinical gastroenterology 43 (3), 267-271, 2009 | 87 | 2009 |
| Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients DH Sinn, GS Choi, HC Park, JM Kim, H Kim, KD Song, TW Kang, MW Lee, ... PLoS One 14 (1), e0210730, 2019 | 85 | 2019 |
| Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B MJ Goh, DH Sinn, S Kim, SY Woo, H Cho, W Kang, GY Gwak, YH Paik, ... Hepatology 71 (6), 2023-2032, 2020 | 81 | 2020 |
| Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy J Bae, DH Sinn, W Kang, GY Gwak, MS Choi, YH Paik, JH Lee, KC Koh, ... Liver International 38 (8), 1442-1448, 2018 | 79 | 2018 |
| Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming DH Lee, SH Kim, W Kang, YS Choi, SH Lee, SR Lee, S You, HK Lee, ... Vaccine 29 (46), 8293-8301, 2011 | 75 | 2011 |
| Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase HA Lee, HW Lee, IH Kim, SY Park, DH Sinn, JH Yu, YS Seo, SH Um, ... Alimentary Pharmacology & Therapeutics 52 (1), 196-204, 2020 | 70 | 2020 |
| Non‐invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low‐level viremia N Paik, DH Sinn, JH Lee, IS Oh, JH Kim, W Kang, GY Gwak, YH Paik, ... Liver International 38 (1), 68-75, 2018 | 62 | 2018 |
| Liver function assessment using albumin–bilirubin grade for patients with very early-stage hepatocellular carcinoma treated with radiofrequency ablation IS Oh, DH Sinn, TW Kang, MW Lee, W Kang, GY Gwak, YH Paik, MS Choi, ... Digestive diseases and sciences 62, 3235-3242, 2017 | 60 | 2017 |
| Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients J Kim, W Kang, DH Sinn, GY Gwak, YH Paik, MS Choi, JH Lee, KC Koh, ... Clinical and molecular hepatology 26 (4), 516, 2020 | 51 | 2020 |
| Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination YS Choi, YH Baek, W Kang, SJ Nam, J Lee, S You, DY Chang, JC Youn, ... Clinical and Vaccine Immunology 18 (9), 1519-1523, 2011 | 45 | 2011 |
| Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial JY Hong, HJ Cho, JK Sa, X Liu, SY Ha, T Lee, H Kim, W Kang, DH Sinn, ... Genome medicine 14, 1-15, 2022 | 40 | 2022 |
| Red cell volume distribution width‐to‐platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B HW Lee, W Kang, BK Kim, SU Kim, JY Park, DY Kim, SH Ahn, YN Park, ... Liver International 36 (1), 24-30, 2016 | 38 | 2016 |
| Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions W Kang, PS Sung, SH Park, S Yoon, DY Chang, S Kim, KH Han, JK Kim, ... Gastroenterology 146 (5), 1351-1360. e4, 2014 | 36 | 2014 |
| Non-invasive prediction of forthcoming cirrhosis-related complications W Kang, SU Kim, SH Ahn World journal of gastroenterology: WJG 20 (10), 2613, 2014 | 36 | 2014 |
| A novel model for predicting hepatocellular carcinoma development in patients with chronic hepatitis B and normal alanine aminotransferase levels DH Sinn, JH Lee, K Kim, JH Ahn, JH Lee, JH Kim, DH Lee, JH Yoon, ... Gut and Liver 11 (4), 528, 2017 | 33 | 2017 |
| Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea MJ Goh, JH Oh, Y Park, J Kim, W Kang, DH Sinn, GY Gwak, YH Paik, ... Liver Cancer 10 (1), 52-62, 2021 | 32 | 2021 |
